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Donor-specific cytotoxic Τ cell activity was measured
over a period of 5 years after transplantation using the
cell-mediated lympholysis (CML) test in 124 recipients
of unrelated kidney allografts who received conven-
tional immunosuppressive therapy consisting of azathi-
oprine and prednisone. Since patients with a functioning
transplant frequently display donor-specific CML non-
responsiveness in vitro, we addressed the question of
whether the CML Status has a predictive value regard-
ing the graft prognosis at any time interval until 5 years
posttransplantation. Front log-rank type analyses we
conclude that the estimated relative risk calculated over
the whole follow-up period of a CML-responder in the
category of transplant rejectors is 1.25 with 95% con-
fidence bounds between 0.94 and 1.65. Measurements
of CML responder Status during follow-up seem to have
only limited prognostic value, although the relative risk
is borderline significant when the analysis is restricted
to the period between 2 weeks and 6 months posttrans-
plantation.
The long-term Immunologie acceptance of a histoincompat-
tble organ graft, which is often assumed to reflect a tolerant
State, could be measured in vitro by the use of the cell-mediated
lympholysis (CML)* assay Penpheral blood lymphocytes from
renal transplant patients with a well-functiomng graft have
often been shown to exhibit donor-specific CML-nonrespon-
siveness (CML-NR) while the CML reactivity against ran
domly ehosen stimulator cells usually remams intact (1-7)
The exact mechamsm(s) that underhe the development of
such donor specific CML-NR after transplantation are not
known, but evidence has been presented that the donor HLA
System may regulate this phenomenon (8) Mechamsms that
may be mvolved mclude the involvement of suppressor cells
(9-14), antudiotypic antibodies (25, 16), Fc receptor blocking
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antibodies (27), antndiotypic Τ cells (28), veto cells (19), or
clonal deletion (13, 20, 21) Since the observations of CML-
NR are essentially retrospective evaluations in selective groups
of patients, we decided to investigate the predictive value of
the CML Status for graft survival Here we present the results
of 372 donor-specific CML studies in 124 renal transplant
recipients in relation to allograft survival
MATERIALS AND METHODS
Patients PBLs from 124 renal patients who had received a first
cadavenc renal transplant through the Services of Eurotransplant were
investigated for their cytolytic potential against donor splenocytes as
well as against control cells From 69 patients additional pretransplant
PBLs were available for study All patients had received one or more
blood transfusion(s) beiore transplantation Immunosuppression con
sisted of prednisone and azathiopnne Transplantation was considered
successful if the recipient remained alive without (re)institution of
dialysis Patients who rejected their graftb were studied till graft ne
phrectomy
In vitro studies Senal samples of recipients' PBLs were collected at
several intervals up to 5 years after transplantation The time mtervals
of blood sample collection and the total number of samples (average 4,
maximum 13) available for study vaned for each patient The PBLs
(ι e 10° responder cells) were sensitized in vitro for 6 days against 108
irradiated splenocytes from the specific kidney donor as well as against
106 control cells from healthy unrelated individuals Depending on the
amount of lymphocytes available, which was limited in most of the
cases, either tissue culture flasks or 2 ml cluster wells were used, the
ratio responder/stimulator celi however is identical in both culture
conditions After the culture period, the effector cells were harvested
and tested in the Standard CML assay against their specific stimulator
cells (ι e splenocytes of the specific kidney donor and control cells of
healthy unrelated individuals) as target cells
Donor lymphocytes were obtained from the spieen All patients'
blood samples, the donor spieen cells, and the control cells were frozen
and stored in hquid nitrogen until used
CML NR or CML R These terms are used to descnbe the CML
nonresponsiveness or CML responsiveness, respectively, exhibited by
the recipients' PBLs against the specific kidney donor splenocytes
Almost all the recipients showed a normal cytolytic response to HLA
incompatible control cells The few cases in which the response to the
control cells remained low in repeated expenments were excluded from
the analyses
The CML assay has been described in detail (22) The percentages
of lysis were determmed using phytohemagglutimn stimulated blast
cells in a 4 hr 'Cr assay Cytotoxicity (i e the amount of isotope
released from 51Cr labeled target cells) was determmed and calculated
according to the described method (22) Standard errors of the mean
of triplicate determinations were less than 5% Positive and negative
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assignments were made on the basis of a 10% specific 51Cr release value
and on a positive slope, ι e the vanous effector to target cell ratios are
plotted and must give an S shaped curve (or in the case of transforimng
the percentage of lysis to a log scale a straight hne) All experiments
were repeated at least twice at different effector to target cell ratios
Statistwal analyses In order to assess the association between CML
responder status during follow up and subsequent graft failure, a log
rank type analysis was performed followmg the method outhned by
Mantel and Byar (23) At each time point t (days posttransplantation)
on which one or more failures occurred, the group of patients at nsk
was divided into two groups, CML NR or CML R, according to their
last CML test done before time t (Patients without CML test before
time t were considered to be not at nsk) Next, for each group the
expected numbers of failures (under the hypothesis that the probabihty
of failure does not depend on the CML Status) were computed in the
usual way Then expected and observed numbers of failures were
compared analogously to the procedure of the Standard log rank test
Two analyses were carned out In the first one the endpoint was
graft failures from all causes mcluding death of the patient In the
second analysis the endpoint was acute rejection Observations of graft
iailures with another cause and observations of patients who died with
a functioning graft were treated as censored in this analysis
RESULTS
Longitudinal CML studies up to 5 years after transplantation
were performed with the lymphocytes from 124 patients who
had received a kidney transplant from an unrelated donor
Three examples of serial investigations are shown in Figure 1
The penod m which the CML responder status may convert
from positive to negative differs between individuals, as exem
phfied in Figure 1
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" Log rank analysis calculated over the whole follow up penod vield
= 0 13
' CML status according to the last previous measurement
In order to assess the relationship between CML status
during follow up and the nsk of graft failure, the log rank
analysis was carned out Table 1 shows the observed and
expected numbers of failures according to CML status at each
time that a failure occurred Although a trend is vjsible (on
average more rejecüons observed than expected in CML R
patients), we could not accept the hypothesis that CML R
patients have more graft failures than CML NR (P = 0 13)
The Mantel Haenszel estimate of the relative nsk (CML R
versus CML-NR) was 1 25 with 95% confidence mterval of
0 94-1 65 Since most renal transplants are lost because of
acute rejection in the first 6 months after transplantation {24),
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we carried out the same analysis for this time traject The
results shown in Table 2 demonstrate that the number of graft
rejections in the CML R group IS higher than expected on the
basis of random distribution of rejection cases between CML-
NR and CML-R patients The effect is most prominent in the
penod between 2 weeks to 6 months posttransplantation, which
just reached statistical significance (P = 0 052)
The statistical analysis as shown above was done based on
the Information that the graft was either "functioning" or
"nonfunctiomng " Therefore "nonfunctioning" grafts included
acute rejections, which were about two thirds of all failures,
recurrent original disease, chromc rejection, death of the pa
tient, or other not further-identified causes of failures Conse
quently, the same statistical analysis was carried out on func-
tionmg renal allografts versus acute rejections only This analy
sis as shown in Table 3 demonstrates that although a trend is
observed similar to the results of the analysis compnsmg all
"nonfunctioning" grafts (Table 2), the data fall to reach statis
tical significance (P = 0 085, posttransplant penod 15-153
days)
We also investigated whether the pretransplant CML Status
has predictive capabihty for the hkelihood of posttransplant
development of CML-NR The availabihty of pretransplant
blood samples of 69 recipients provided the Information con
cerning the donor-directed CTL reactivity prior to grafting
Fifty one recipients showed CML reactivity against the splen-
ocytes of the kidney donor Twenty eight of 51 patients who
exhibited pretransplant CML reactivity developed donor-spe-
cific CML nonreactivity at different times posttransplant,
whereas 23 patients persistently demonstrated donor-directed
CTL activity, 15 pretransplant CML NR patients remained
TABLE 2 Results of log rank analyses for the relationship between
CML Status and graft survival" in some different time trajects
in aays
0-2421
0 183
15-183
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(95% confidence
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1 25 (0 94-1 65)
1 69 (0 92-3 09)
2 04 (0 99-4 17)
1 62 (0 79-3 33)
1 04 (0 79-1 37)
° Endpoint is> graft failure from all causes (death of a patient always
being considered as graft failure)
" See legends Table 1
Whole penod
TABLE 3 Results of log rank analyses for the rflationship between
CML Status and graft survival" in some different time trajetts
Penod
in days
0-2073
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CML
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5
3
3
7
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Ν
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7
3
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13 60
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5 43
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Ρ value
0 18
0 17
0 085
0 32
0 75
Estimated relative
nsk
(95% confidence
bounds)
1 29 (0 89-1 86)
1 60 (0 82-3 11)
2 08 (0 90-4 73)
1 53 (0 66-3 53)
1 06 (0 73-1 55)
Endpoint is acute rejection (observations of patients who die with
iunctiomng grafts are censored)
See legends Table 1
Whole penod
CML NR posttransplantation Three patients with acute irre
versible rejection showed "reversed" CML conversion absence
of pretransplant donor directed CTL activity but high levels of
cytotoxic activity shortly after grafting pnor to graft nephrec-
tomy Acute irreversible graft rejection was observed within 7,
12, and 15 days, respectively, this "reversed conversion" of
CML NR pretransplant to CML-R posttransplant might ap-
pear to be an indication for poor graft survival
DISCUSSION
In vitro donor specific cell-mediated lympholysis nonrespon-
siveness exhibited by cells from recipients with well-function-
mg kidney allografts is a generally observed association (1-7).
All studies except one (6) were carried out with a short-time
follow-up Notwithstanding these observations, we assessed to
what extent this apparent m vitro reflection of acqmred toler-
ance can be explained by selection for patients who get the
chance to develop CML-NR The availabihty of over 350 CML
studies in 124 renal transplant patients with a follow-up penod
of approximately 5 years enabled us to investigate whether the
CML NR predicts graft survival durmg follow-up
By assessing the correlation of the outcome of the CML tests
and graft survival for different time intervals, lt appeared that
only the posttransplant penod between 2 weeks and 6 months
showed a (marginally) significant correlation (P = 0 05) be-
tween CML-NR and graft survival on one hand, and CML-R
and graft lost on the other hand; the data failed however to
reach statistical significance when analyzmg only the acute
rejections (P = 0 085, Table 3) Nevertheless, these trends
could be of mterest in view of the chnical observation that most
acute rejection episodes occur within this time penod (24) The
results obtained with the 69 patients senally momtored from
pre- to posttransplantation demonstrated that pretransplant
donor-directed CTL activity is not a contraindication for trans-
plantation and does not preclude the development of CML NR
posttransplantation Conversely, pretransplant CML-NR con
verting shortly after transplant to CML-R was in 3 out of 3
cases associated with acute rejection and graft loss
It also appeared from our studies that several patients had a
well-functioning graft while demonstrating in vitro donor-spe-
cific CML activity, hkewise a number of patients rejected their
graft despite their CML-NR Status The Situation in which
patients with a well-functioning graft show in vitro donor-
specific CML activity is compatible witb the experimental
animal studies in which specific cytotoxic Τ cells were found
m nonrejected rat kidneys (25) The cellular mechanism of
graft destruction is probably composed of phenotypically and
functionally different Τ cell subsets directed against MHC class
I and class II transplantation antigens, as was recently reported
by Miceh et al (26) and by Bonneville et al (27) These
observations are consistent with the findmgs that cytotoxic Τ
effector cells are not the sole mediators of graft rejection as
was first observed by Loveland et al (28) Although these and
numerous experimental animal studies that followed (29),
which were designed to unravel the effector mechamsms of
allograft rejection, concern skin grafting in nonimmune sup-
pressed animals, they provide important msights mto the com
piexity of Immunologie responses in human allograftmg. Effec-
tor mechamsms operatmg in vascularized human allograft re-
jection are also dependent on the genetic constitution of the
recipient (30), and antigen expression Status of the graft (31,
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32). Furthermore, pretransplant blood transfusions are known
to have a beneficial effect on kidney graft prognosis (33, 34)
We reported earlier that CML-NR occurs with the same fre-
quency in both smgle and multitransfused patients (4). Re-
cently, we designed a prospective study to analyze blood-trans-
fusion-mduced changes in cellular and humoral lmmumty (35)
Prehminary results of this ongoing study show that lf the
transfusion donor and recipient are mismatched for both HLA-
DR antigens, the recipient IS immunized resulting in a transient
increase of cytotoxic activity, after an HLA DR shared trans-
fusion, the in vitro test remained unchanged or shghtly de-
creased. However in none of cases studied so far, has lt led to
CML-NR
Α method of monitoring the graft certamly is to perform
graft biopsies (36) or fine-needle aspirates (37) The in vitro
monitoring by measurement of the donor-directed cytotoxic Τ
cell activity as described herein may provide further Informa-
tion regardmg acute rejection Although predictions regardmg
the likehhood of the occurrence of posttransplant CML-NR
must be made with great caution, posttransplant monitoring
usmg the CML assay may at least for the first 6 months after
transplantation be helpful for the Interpretation of chnical
events and possibly for the design of therapeutic strategies
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MECHANISMS OF INSULIN RESISTANCE AFTER KIDNEY
TRANSPLANTATION1
AGNETA EKSTRAND, JUHANI AHONEN, CAROLA GRONHAGEN-RISKA, AND L E I F G R O O P 2
Fourth Department of Mediane and Fourth Department of Surgery, Helsinki Unwersity Hospital, Helsinki, Fmland
In order to study the effect of corticosteroids on energy
metabolism in immunosuppressed patients after kidney
transplantation, we have examined glucose utilization,
energy expenditure, and lean body mass in 10 kidney-
transplanted patients receiving steroids (methylpred-
nisolone 8.2±1.5 mg/day) and in 10 healthy age- and
weight-matched control subjects. Glucose utilization
was measured during euglycemic insulin clamp in com-
bination with indirect calorimetry and infusion of [3H-
3]-glucose, while /?-cell function was measured during a
hyperglycemic clamp. The kidney-transplanted patients
were resistant to the glucoregulatory effect of insulin,
as demonstrated by a 25% reduction in total glucose
disposal compared to control subjects. This defect was
almost completely accounted for by a defect in storage
of glucose as glycogen (3.3±0.5 vs. 5.0+0.5 mg/kgLBM-
min; P<0.05). The reduction in nonoxidative glucose
disposal was associated with reduced lean body mass
and incapacity to release energy as heat after infusion
of insulin, i.e. thermogenic defect. In contrast, oxidation
of glucose and Iipids was not influenced by steroid ther-
apy. Futhermore, suppression of hepatic glucose produc-
tion was normal, and insulin secreiion was normally
enhanced in relation to the degree of insulin resistance
in the steroid-treated patients. In conclusion, steroid-
induced insulin resistance in kidney-transplanted pa-
tients is due to alterations in the nonoxidative pathway
of glucose metabolism. These findings raise the question
1
 This work was supported in part by the Finska Lakaresallskapet
(Finnish Medical Society), Munuaissaatio (Kidney Foundation), the
Sigrid Jusehus Foundation, and the Farmos Science Foundation
2
 Address correspondence to Leif Groop, Fourth Department of
Mediane, Helsinki University Hospital, Umoninkatu 38, SF-00170
Helsinki, Finland
of whether steroid therapy directly influences glycogen
synthase in man.
Despite the introduction of cyclosporine and other new drugs,
corticosteroids have been the cornerstone in immunosuppres-
sive therapy after kidney transplantation. Steroids have been
known to induce insulin resistance in experimental animals
(1, 2) and in man (3-5). Several mechanisms have been sug-
gested to explain the steroid-induced insulin resistance, e.g.
decreased insulin receptor number and affinity (6, 7), impaired
peripheral glucose uptake (primarily in muscle) (8), impaired
suppression of endogenous glucose production (9), and activa-
tion of the glucose/fatty acid (FFA)* cycle initially proposed by
Rändle et al. (20). The glucose/FFA cycle is based upon the
concept of Substrate competition, i.e. increased utilization of
FFA leads to decreased utilization of glucose and vice versa. In
addition to effects on glucose metabolism, steroids are known
to induce protein catabolism (11). The chmcal consequence is
wasting of muscle tissue. The majority of glucose after a meal
is taken up by muscle tissue (12,13), where it is metabolized
by either of two pathways: oxidation to carbon dioxide and
water, or storage as glycogen. Total body glucose metabolism
has been shown to correlate with the muscle mass (14), but it
is not known whether insulin resistance correlates with muscle
wasting during chronic steroid therapy.
The clinical endpomt of insulin resistance is diabetes melli-
tus. The incidence of secondary diabetes after kidney trans-
plantation has markedly increased over the past years (15,16).
There may be several explanations for this phenomenon: mclu-
sion of older patients in transplantation programs and the use
' Abbreviations FFA, glucose/fatty acid, HGP, hepatic glucose pro-
duction
